Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)
Harper, Scott Q.
UMass Chan AffiliationsWellstone Center for FSHD
Document TypeJournal Article
Nervous System Diseases
MetadataShow full item record
AbstractFacioScapuloHumeral muscular Dystrophy (FSHD) is one of the most prevalent hereditary myopathies and is generally characterized by progressive muscle atrophy affecting the face, scapular fixators; upper arms and distal lower legs. The FSHD locus maps to a macrosatellite D4Z4 repeat array on chromosome 4q35. Each D4Z4 unit contains a DUX4 gene; the most distal of which is flanked by a polyadenylation site on FSHD-permissive alleles, which allows for production of stable DUX4 mRNAs. In addition, an open chromatin structure is required for DUX4 gene transcription. FSHD thus results from a gain of function of the toxic DUX4 protein that normally is only expressed in germ line and stem cells. Therapeutic strategies are emerging that aim to decrease DUX4 expression or toxicity in FSHD muscle cells. We review here the heterogeneity of DUX4 mRNAs observed in muscle and stem cells; and the use of antisense oligonucleotides (AOs) targeting the DUX4 mRNA to interfere either with transcript cleavage/polyadenylation or intron splicing. We show in primary cultures that DUX4-targeted AOs suppress the atrophic FSHD myotube phenotype; but do not improve the disorganized FSHD myotube phenotype which could be caused by DUX4c over-expression. Thus; DUX4c might constitute another therapeutic target in FSHD.
SourceGenes (Basel). 2017 Mar 3;8(3). pii: E93. doi: 10.3390/genes8030093. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/50569
Related ResourcesLink to Article in PubMed
RightsCopyright © 2017 by the authors. Licensee MDPI, Basel, Switzerland.
Except where otherwise noted, this item's license is described as Copyright © 2017 by the authors. Licensee MDPI, Basel, Switzerland.